ROI Analytics

Returns on capital allocated to research directions — value generated per 1000 tokens invested

Analyses Tracked

486

Mean ROI

+22.20

Median ROI

+7.09

Underperforming

High-Potential

104

Analysis ROI Rankings (Top 50)

Analysis	ROI (per 1K tokens)
TREM2 agonism vs antagonism in DAM microglia	+4941.05
Seed-competent tau conformers in trans-synaptic sp	+264.90
Orexin-A manipulation in AD cognition and circadia	+220.51
Senolytic therapy for age-related neurodegeneratio	+138.75
SEA-AD Gene Expression Profiling — Allen Brain Cel	+121.40
Digital biomarkers and AI-driven early detection o	+111.45
Blood-brain barrier transport mechanisms for antib	+98.49
CRISPR-based therapeutic approaches for neurodegen	+94.85
Ferroptosis in ALS motor neuron vulnerability	+90.94
Gene expression changes in aging mouse brain predi	+81.39
TREM2 agonism vs antagonism in DAM microglia	+67.95
What are the mechanisms by which gut microbiome dy	+55.17
Sleep disruption as cause and consequence of neuro	+50.72
Is APOE4's reduced lipid binding pathogenic or a c	+49.93
Epigenetic reprogramming in aging neurons	+48.57
Mitochondrial transfer between astrocytes and neur	+47.98
Astrocyte reactivity subtypes in neurodegeneration	+46.80
Cell-Cell Communication Analysis in AD Brain Micro	+44.08
Perivascular spaces and glymphatic clearance failu	+42.81
Mechanistic role of APOE in neurodegeneration	+41.28
Neuroinflammation resolution mechanisms and pro-re	+40.42
Epigenetic clocks and biological aging in neurodeg	+40.09
APOE4 structural biology and therapeutic targeting	+39.65
Autophagy-lysosome pathway convergence across neur	+38.18
Selective vulnerability of entorhinal cortex layer	+38.02
Circuit-level neural dynamics in neurodegeneration	+36.06
Can circadian interventions reverse microglial pri	+34.89
How does gut microbiome dysbiosis contribute to ne	+34.27
Microglia-astrocyte crosstalk amplification loops	+33.55
Lipid raft composition changes in synaptic neurode	+32.69
RNA binding protein dysregulation across ALS FTD a	+31.56
De Novo Binder Design Targeting Alpha-Synuclein Ag	+31.42
Mitochondrial transfer between neurons and glia	+31.10
How does parthenolide specifically modulate ADORA2	+30.55
4R-tau strain-specific spreading patterns in PSP v	+30.32
How does ADCY8 mechanistically regulate long-term	+30.19
What specific autophagy pathways are defective in	+29.63
Which specific transcription factors mediate MAPT	+29.25
Are age-related DNA methylation changes protective	+28.19
Gene Co-expression Network Analysis of AD Progress	+28.01
Cell type vulnerability in Alzheimer's Disease (SE	+27.62
Legacy Pre-Pipeline Hypothesis Import	+27.58
Cell type vulnerability in Alzheimers Disease (SEA	+26.42
Are DNA methylation changes in neurodegeneration c	+25.47
Neuroinflammation and microglial priming in early	+25.43
TREM2 in Alzheimer's Disease: Mechanisms, Therapeu	+25.24
Synaptic pruning by microglia in early AD	+24.95
Blood-brain barrier permeability changes as early	+24.68
Which specific CSF molecular components are essent	+24.48
Are interneuron oscillation deficits compensatory	+24.42

Underperforming Research (Bottom 20%)

Analyses with lowest ROI — consider reallocating capital away from these directions

Analysis	ROI
Does CXCL10 inhibition compromise CNS immune surve	+2.63
Test	+2.60
What molecular mechanisms determine whether reacti	+2.60
Blood-brain barrier transport mechanisms for antib	+2.56
test	+2.54
What specific gene expression signatures in aging	+2.54
How do ALS-associated OPTN mutations mechanistical	+2.53
scRNA-seq Processing and Cell Type Annotation of A	+2.52
Selective vulnerability of entorhinal cortex layer	+2.48
Test	+2.47
What determines blood-brain barrier penetration ki	+2.45
Do SPM receptors undergo desensitization with chro	+2.42
What are the specific molecular determinants that	+2.36
Can P16INK4A expression reliably distinguish harmf	+2.35
How does pericyte senescence mechanistically promo	+2.33
What are the molecular signatures that distinguish	+2.32
Gene expression changes in aging mouse brain predi	+2.27
What mechanisms explain how IDH1/IDH2 mutations wi	+2.27
Why do TAM receptors protect against neuroinvasive	+2.23
Do oligodendrocytes require DNA repair enhancement	+2.23

High-Potential Underfunded

Strong quality hypotheses but low token investment — prime candidates for additional funding

Analysis	Hypotheses	Tokens Spent	Avg Quality
Test	7	15,082	0.591
Test	7	17,409	0.615
Test	7	13,841	0.546
Test	7	14,491	0.651
Test	7	9,641	0.589
Test	7	10,712	0.607
Test	7	10,516	0.599
Cross-disease neurodegeneration mechanis	17	14,893	0.745
Gamma entrainment therapy to restore hip	7	11,661	0.734
Closed-loop optogenetic targeting PV int	7	14,448	0.594
GluN2B-Mediated Thalamocortical Control	7	12,593	0.666
Methodology challenge: dataset 'Allen Br	7	12,956	0.605
Test Preregistration Analysis	7	11,924	0.616
What is the optimal dosage and timing of	7	13,387	0.526
How does the intron-retained RNA isoform	7	13,889	0.552
What blood-brain barrier permeability ch	8	13,205	0.643
What blood-brain barrier permeability ch	8	11,859	0.676
How does gut microbiome dysbiosis contri	7	15,405	0.617
What blood-brain barrier permeability ch	8	12,330	0.679
TREM2 in Alzheimer's Disease: Mechanisms	8	8,603	0.590

ROI = (hypotheses_generated × avg_quality × 10 + KG_edges × 2) / total_tokens × 1000
Higher ROI indicates more research value generated per token invested.